Measurement of anti-drug antibodies to biologic drugs

Rheumatology (United Kingdom)

Volumn 54, Issue 11, 2015, Pages 1941-1943

  Felis Giemza, Anna ^a   Moots, Robert J ^b  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL PRODUCT; DRUG ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M ANTIBODY; METHOTREXATE; NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; BIOLOGICAL THERAPY; DRUG HYPERSENSITIVITY; EDITORIAL; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY BOWEL DISEASE; MEASUREMENT; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT RESPONSE;

EID: 84946737279     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev279     Document Type: Editorial

References (10)

1. Vincent FB, Morand EF, Murphy K et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.
2. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164-72.
3. Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 2013;173:1416-28.
4. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
5. Bender NK, Heilig CE, Droll B et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007;27:269-74.
6. Papp K, Crowley J, Ortonne JP et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011;164:434-41.
7. Jani M, Barton A, Warren RB, Griffiths CEM, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology 2014;53:213-22.
8. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947-55.
9. Garcês S, Antunes M, Benito-Garcia E et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2014;73:1138-43.
10. Wright H, Thomas H, Moots RJ, Edwards SW. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. Rheumatology 2015;54:188-93.